BUDGET IMPACT ANALYSIS OF APREMILAST ON MODERATE TO SEVERE PSORIASIS IN SPAIN

被引：0
|
作者：
Vanaclocha, F. [1 ]
Carrascosa, J. M. [2 ]
Caloto, T. [3 ]
Elias, I [4 ]
Echave, M. [4 ]
Tencer, T. [5 ]
机构：
[1] 12 Octubre Univ Hosp, Dept Dermatol, Madrid, Spain
[2] Germans Trias & Pujol Univ Hosp, Dept Dermatol, Barcelona, Spain
[3] Celgene Corp, Dept Econ, Madrid, Spain
[4] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[5] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.559
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS35
引用
收藏
页码：A421 / A421
页数：1
相关论文
共 50 条
  • [31] Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
    Okubo, Yukari
    Ohtsuki, Mamitaro
    Komine, Mayumi
    Imafuku, Shinichi
    Kassir, Nastya
    Petric, Rosemary
    Nemoto, Osamu
    JOURNAL OF DERMATOLOGY, 2021, 48 (11) : 1652 - 1664
  • [32] Apremilast in moderate-to-severe plaque psoriasis (ESTEEM 2 trial)
    Anstey, Alex
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) : E23 - E23
  • [33] COST OF MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN
    Sanchez-Carazo, J. L.
    Dauden, E.
    Vanaclocha, F.
    Toribio, J.
    Pujol, R.
    Puig, L.
    Yebenes, M.
    Sabater, F. J.
    VALUE IN HEALTH, 2009, 12 (07) : A454 - A454
  • [34] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE ITALIAN SETTING
    Barbieri, M.
    Capri, S.
    Oskar, B.
    VALUE IN HEALTH, 2015, 18 (07) : A419 - A420
  • [35] Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK
    Mughal, F.
    Barker, J.
    Cawston, H.
    Damera, V.
    Bewley, A.
    Morris, J.
    Shaw, T.
    Tencer, T.
    Zhang, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 74 - 74
  • [36] Impact of moderate/severe psoriasis on employment
    Cusack, C
    Buckley, C
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 : 34 - 34
  • [37] QUALITY OF LIFE IN MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN
    Puig, L.
    Sanchez-Carazo, J. L.
    Dauden, E.
    Vanaclocha, F.
    Toribio, J.
    Pujol, R.
    Casado, M. A.
    Sabater, F. J.
    VALUE IN HEALTH, 2008, 11 (06) : A621 - A621
  • [38] BUDGET IMPACT ANALYSIS OF IXEKIZUMAB, GUSELKUMAB, RISANKIZUMAB AND/OR SECUKINUMAB FOR MANAGEMENT OF MODERATE-TO-SEVERE PSORIASIS IN THE KINGDOM OF SAUDI ARABIA
    Al Jedai, A.
    AL-Mudaiheem, H.
    Aldail, M.
    Fatani, M.
    Binamer, Y.
    Sharma, Y.
    Mohamed, O.
    Awad, N.
    Al-Amaa, T.
    VALUE IN HEALTH, 2020, 23 : S17 - S17
  • [39] The impact of apremilast therapy on work productivity among patients with moderate to severe plaque psoriasis: Pooled analysis of 2 phase 3 studies
    Papp, Kim
    Zhang, Frank
    Tencer, Tom
    Li, Stan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB255 - AB255
  • [40] COST PER RESPONDER OF APREMILAST VERSUS INFLIXIMAB BIOSIMILAR, ETANERCEPT, ADALIMUMAB, USTEKINUMAB AND SECUKINUMAB IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN SPAIN
    Martinez-Sesmero, J. M.
    Schoendorff, C.
    Caloto, T.
    VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
12345